Cuspa Medical, an Israeli medtech startup, offers a first-of-its-kind heart valve repair device that the company boasts will save over 10 million patients the world over who suffer from heart valve insufficiency who do not have an effective alternative today. Cuspa’s implant seals heart valves in a minimally invasive procedure, avoiding an invasive open heart surgery and providing immediate symptom relief to the patient.
Israel Startup Nation may best be known for its high-tech innovations and cyber security firms, but it is also known for its medical and scientific advancements. Israeli researchers are at the forefront of new cancer treatments. Israeli startups like NeuroSense Therapeutics is working on a new technology that utilizes artificial intelligence AI to detect ALS, also known as Lou Gehrig’s disease. And others like Ossio develop orthopedic fixation technology and Olive Diagnostics offers KG, the world’s first artificial intelligence (AI)-based optical device capable of early detection of diseases at home or in the clinic.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
According to the Mayo Clinic, in heart valve disease, one or more of the valves in your heart doesn’t work properly. Your heart has four valves that keep blood flowing in the correct direction. In some cases, one or more of the valves don’t open or close properly. This can cause the blood flow from your heart to your body to be disrupted.
And Cuspa Medical explains that your heart valve disease treatment depends on the heart valve affected and the type and severity of the disease. Sometimes heart valve disease requires surgery to repair or replace the heart valve.
Heart valve insufficiency causes the leakage of blood through a malfunctioning heart valve. Specifically, Aortic Regurgitation (AR) is a condition where the aortic valve fails, allowing backflow of blood from the aorta to the left ventricle of the heart. Structural changes to the structures around the aortic valve can cause the leaflets to not close properly, leaving a central jet of backflow during the diastole phase of the heart cycle. If left untreated, AR can lead to life-debilitating symptoms including heart palpitations, chest pain, fatigue, or shortness of breath and ultimately leads to heart failure. The 5-year survival rate of untreated patients suffering from severe symptomatic AR and classified as NYHA class 3-4 stands at 28±12% representing a high risk for this patient population, specifically those with prohibited or high operative risk. These patients are longing for a solution that increases survival rate, and minimizes side effects and risks.
The Cusper technology was invented by Doctor Yair Feld, MD and PhD and founder of Cuspa. The idea came to him after seeing a patient with AR that was referred to TAVI, but the procedure failed and the patient was rushed to emergency surgery. Dr Feld has conducted intense research and multiple tests before founding Cuspa and working the process of bringing this life-changing innovation to a complete and authorized medical approved product. The company is run by Co-founder and CEO, Ariel Weigler, Ms.c. Mr. Weigler is an experienced R&D engineer with a proven track-record leading multidisciplinary teams. Has led the development from concept to clinical trials of a novel non-invasive blood testing system as well as projects at Philips Healthcare as a process engineer.
Cusper will bring a first-of-its-kind innovative approach to the medical world, providing a highly valued treatment to the AR condition. With Cusper, there is no need for invasive open heart surgeries, which are extremely dangerous to the patient, require a long recovery period and are a costly procedures. Cusper is an artificial cusp, attached to the native aortic valve cusp using a Nitinol grasper. Cusper’s unique design secures the implant to the native valve using an atraumatic grasper, allowing normal cusp motion and preserving the native anatomy. With Cusper, a huge patient population suffering from AR, including patients who are not surgical candidates, can finally have their aortic valve repaired in a minimally invasive, safe, effective and easy-to-use procedure.
The Cusper is currently being tested in large animals to test device safety and efficacy.The company has 2 international patents pending approval in the US,Europe, China, Israel, Japan, Korea and Canada. World-renowned interventional cardiologists have joined Cuspa’s Scientific Advisory Board such as Prof.Giora Weisz from Columbia University hospital and Prof. Felix Mahfoud from Homburg university hospital, Germany.
